Breaking Finance News

Codexis, Inc. (NASDAQ:CDXS) has been downgraded to Sell in a statement by ValuEngine earlier today.

Having a price of $5.25, Codexis, Inc. (NASDAQ:CDXS) traded -1.87% lower on the day. With the last close up 11.27% from the two hundred day average, compared with the S&P 500 Index which has increased 0.05% over the same period. Codexis, Inc. has recorded a 50-day average of $5.35 and a two hundred day average of $4.72. Volume of trade was up over the average, with 198,309 shares of CDXS changing hands over the typical 139,134

ValuEngine has downgraded Codexis, Inc. (NASDAQ:CDXS) to Sell in a statement released on 07/06/2017.

Performance Chart

Codexis, Inc. (NASDAQ:CDXS)

With a total market value of $0, Codexis, Inc. has with a one year low of $3.60 and a one year high of $5.70 .

More About Codexis, Inc. (NASDAQ:CDXS)

Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company's CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company's pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.